| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
Zeno Equity Partners presents a detailed investment thesis on Danaher, their largest position, arguing it exemplifies their strategy of identifying companies with market power, sustainable high returns, and a founder's mindset focused on disciplined capital allocation. Danaher operates across three healthcare segments: Biotechnology (30% of revenues, 40% of profits), Diagnostics (40% of both), and Life Sciences (20% of profits), all benefiting from secular growth trends in aging populations, rising disease incidence, and technological advances. The Biotechnology segment, operating under the Cytiva brand, is described as the crown jewel with 88% recurring revenues and industry-leading 40% EBIT margins, particularly strong in chromatography purification with ~70% market share. Diagnostics demonstrates strong switching costs and vendor reputation barriers with 29% EBIT margins. The manager acknowledges mistakes in Life Sciences, particularly the Aldevron and Abcam acquisitions which have destroyed value. Despite recent headwinds from COVID normalization, biotech funding winter, China pricing pressure, and Trump administration policies, the manager believes these events have delayed rather than derailed returns. At a ~5% free-cash-flow yield with expected high-single-digit to low-double-digit earnings growth over the next decade, the manager views Danaher as offering compelling risk-adjusted returns.
Danaher is a high-quality business demonstrating market power and rewarding reinvestment opportunities across its Biotechnology, Diagnostics, and Life Sciences segments, driven by secular healthcare trends, strong switching costs, recurring revenue models, and the application of the Danaher Business System to drive continuous operational improvement.
The manager is confident that Danaher will continue to compound at very attractive returns for a very long time, despite disappointing total shareholder returns over the past five years. The manager believes external shocks have delayed rather than derailed the realization of shareholder returns, and the industry's eventual recovery is extremely likely given the strength of secular drivers. The manager expects the combined business can credibly deliver high-single-digit to low-double-digit earnings growth over the next decade.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jul 23 2026 | 2026 Q2 | DHR | Biotechnology, Capital Allocation, Danaher, Diagnostics, healthcare, Life Sciences, Market Power, Quality | DHR | Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences. The Biotechnology segment is the crown jewel with 88% recurring revenues and 40% EBIT margins, particularly dominant in chromatography purification. Recent headwinds from COVID normalization, biotech funding winter, and policy uncertainty have delayed but not derailed the thesis. At 5% FCF yield with high-single-digit to low-double-digit growth potential, risk-adjusted returns are compelling. |
| May 23 2026 | 2026 Q1 | AMZN, PAX, RENT3.SA, VIST | AI, Argentina, Brazil, contrarian, Latin America, oil, value |
RENT3.SA VIST PAX |
Zeno deliberately avoids the AI bubble while aggressively deploying into undervalued Latin American opportunities. The fund increased LatAm exposure to 28%, buying quality businesses like Localiza and Vista Energy at attractive valuations following currency weakness and investor capitulation. This contrarian approach reflects their core philosophy of finding disconnects between price and fundamental value. |
| Jan 21 2026 | 2025 Q4 | BRK-A, DHR, FTV, GE, ITW, JCI, NVST, VRLT | Biotechnology, Capital Allocation, Conglomerates, Ownership, Spin-Offs, value creation | DHR | Danaher represents the power of founder-led ownership in creating long-term value. The Rales brothers transformed a diversified conglomerate into a pure-play bioprocessing leader through strategic spin-offs and acquisitions, compounding at 21% annually over 40 years. This patient capital approach and willingness to abandon successful strategies when necessary exemplifies superior risk-adjusted decision making. |
| Oct 21 2025 | 2025 Q3 | APH, CSU.TO, CTAS, DHR, EZJ.L, HCSG, LIN, ODFL, RYAAY, SNBR, TPG | Capital Allocation, compensation, execution, management, Ownership, Quality, returns | - | Zeno seeks companies led by owner-operators with Founder's Mindset who combine strong execution with disciplined risk assessment. Their portfolio companies like Amphenol, Linde, and Ryanair have management teams owning hundreds of millions in equity, delivering mid-teens returns through superior long-term decision making that prioritizes competitive positioning over short-term metrics. |
| Jun 30 2025 | 2025 Q2 | AAPL, ADI, IFX.DE, TSM, TXN | Analog, Automotive, Cyclical, Industrial, Manufacturing, Onshoring, semiconductors, technology |
TXN TXN |
Zeno added Texas Instruments in January 2024 as a long-term holding in analog semiconductors. TI's focus on catalog chips with multi-decade lifecycles, operational manufacturing excellence, and strategic US fab investments position it for sustained FCF growth. Despite cyclical headwinds, the fund expects 12%+ earnings growth and mid-teens IRR through superior competitive positioning. |
| Mar 31 2025 | 2025 Q1 | AMZN | Customer, E-Commerce, innovation, Leadership, long-term, technology, value | AMZN | Zeno holds Amazon as their only mega cap tech investment due to its unique Founders Mindset culture. Amazon consistently prioritizes long-term customer value over short-term profits through decisive leadership, collaborative innovation, and ownership mentality. This approach creates sustainable competitive advantages and high incremental returns, differentiating it from peers like Microsoft and Google. |
| Dec 31 2024 | 2024 Q4 | - | active management, Concentration, long-term, Quality, risk management, value | - | Zeno redefines active management as concentrated investing in exceptional businesses for long-term wealth protection rather than benchmark outperformance. They seek companies with Founder Mindset, Market Power and Reinvestment opportunity that can compound through economic cycles. The fund prioritizes business quality over diversification, expecting their concentrated approach to protect capital during inevitable market corrections while generating superior long-term returns. |
| Sep 30 2024 | 2024 Q3 | MC.PA | Brand Power, Long Term, Luxury, LVMH, Market share, valuation | - | LVMH represents the ultimate luxury franchise with unassailable brand power and distribution scale. Despite current cyclical headwinds causing near-term underperformance, the company's sustainable competitive advantages and Arnault's long-term stewardship create a compelling path to double-digit returns as luxury consumption normalizes and market share consolidation continues favoring mega-brands. |
| Jul 16 2024 | 2024 Q2 | AER, AIR.PA, BA, DHR, GE, GEHC, GEV, HEI, HON, PH, SAF.PA, TDG | aerospace, Aftermarket, Concentration, Market Power, value | - | Zeno's largest position GE Aerospace leverages 70% commercial engine market share and razor-blade aftermarket model generating 3.5x engine sale revenue. High switching costs from regulatory requirements and complexity create sustainable pricing power. CEO Larry Culp's operational discipline and $300M+ ownership align interests. Secular air travel growth and efficiency-driven fleet upgrades support mid-single digit volume growth and low-double digit cash flow expansion. |
| Jun 30 2024 | 2024 Q2 | AER, AIR.PA, BA, DHR, GE, GEHC, GEV, HEI, HON, PH, SAF.PA, TDG | aerospace, Aftermarket, Concentration, Market Power, value | GE | Zeno's largest position GE Aerospace leverages 70% commercial engine market share and razor-blade aftermarket model generating 3.5x engine sale revenue. High switching costs from regulatory requirements and complexity create sustainable pricing power. CEO Larry Culp's operational discipline and $300M+ ownership align interests. Secular air travel growth and efficiency-driven fleet upgrades support mid-single digit volume growth and low-double digit cash flow expansion. |
| Mar 31 2024 | 2024 Q1 | - | Capitalism, concentrated, long-term, Philosophy, Quality, value creation | - | Zeno runs a concentrated 19-stock portfolio targeting rare companies that have escaped capitalism's competitive forces through system failures. They seek businesses earning excess profits managed by long-term oriented leaders who balance stakeholder interests. The fund completed its independence from Dynamo while acknowledging the extreme rarity of companies meeting their criteria. |
| Jan 23 2024 | 2023 Q4 | APH, AZE.BR, CSU.TO, DHR, DSGX.TO, GE, HEI, IPUMP.MI, LIN | Founder Mindset, Investment Criteria, Market Power, Portfolio Transition, Quality | - | Zeno completed major portfolio restructuring, selling eight companies and buying nine new investments that better align with their three investment criteria: market power, reinvestment opportunity, and founder mindset. New holdings include quality names like Constellation Software, Danaher, and Linde. Portfolio changes should normalize going forward with minimal turnover expected. |
| Dec 31 2023 | 2023 Q4 | APH, AZE.BR, CSU.TO, DHR, DSGX.TO, GE, HEI, IPUMP.MI, LIN | Founder Mindset, Investment Criteria, Market Power, Portfolio Transition, Quality | - | Zeno completed major portfolio restructuring, selling eight companies and buying nine new investments that better align with their three investment criteria: market power, reinvestment opportunity, and founder mindset. New holdings include quality names like Constellation Software, Danaher, and Linde. Portfolio changes should normalize going forward with minimal turnover expected. |
| Dec 18 2023 | 2023 Q3 | - | Concentration, Europe, long-term, Quality, value | - | Zeno Equity Partners launches with a concentrated value strategy targeting 25 companies in Europe and Americas. The fund seeks businesses with Market Power, Reinvestment Opportunity, and Founder Mindset, expecting 12-15% annual returns over 5+ years. Large positions are 10-15% of NAV in a low-turnover portfolio focused on long-term free cash flow growth. |
| Nov 30 2023 | 2023 Q3 | - | Concentration, Europe, long-term, Quality, value | - | Zeno Equity Partners launches with a concentrated value strategy targeting 25 companies in Europe and Americas. The fund seeks businesses with Market Power, Reinvestment Opportunity, and Founder Mindset, expecting 12-15% annual returns over 5+ years. Large positions are 10-15% of NAV in a low-turnover portfolio focused on long-term free cash flow growth. |
| - | 2023 Q2 | APPF | Market Power, Property Management, Reinvestment, SaaS, Vertical Software | - | AppFolio dominates property management software with high switching costs and strong unit economics. The company serves 8 million of 79 million addressable units with 30% revenue CAGR since IPO. Patient capital from IGSB enables long-term reinvestment. Despite rich 9x revenue valuation, underlying earnings multiple of 30x for 20%+ growth appears attractive for long-term investors. |
| Jul 18 2023 | 2023 Q2 | APPF | Market Power, Property Management, Reinvestment, SaaS, Vertical Software | APPF | AppFolio dominates property management software with high switching costs and strong unit economics. The company serves 8 million of 79 million addressable units with 30% revenue CAGR since IPO. Patient capital from IGSB enables long-term reinvestment. Despite rich 9x revenue valuation, underlying earnings multiple of 30x for 20%+ growth appears attractive for long-term investors. |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2026 Q2 |
BiotechnologyDanaher's Biotechnology segment (Cytiva) is described as the crown jewel, generating ~30% of revenues and ~40% of profits with 88% recurring revenues. The segment sells equipment and consumables for manufacturing biologics under a razor-razorblade model. Biologics have grown from less than 20% to roughly half of the industry pipeline, with dollar sales tripling over the past decade. The manager expects biologic drug volume to grow high-single-digit for the next decade, driven by aging populations, rising disease incidence, and growing share of biologics within the overall drug mix. |
Biologics Bioprocessing Cytiva Recurring Revenue Pharmaceuticals |
DiagnosticsDanaher's Diagnostics segment contributes roughly 40% of revenues and profits, selling instruments and consumables for clinical and molecular testing with ~90% recurring revenues. The manager highlights strong switching costs, vendor reputation barriers, and industry-leading 29% EBIT margins with over 90% cash conversion. The manager expects mid-single-digit growth driven by aging populations, lifestyle shifts increasing chronic conditions, technological progress in oncology and neurodegenerative testing, and rising emerging market income. |
Clinical Testing Molecular Diagnostics Switching Costs Healthcare | |
Life Science ToolsThe Life Sciences segment constitutes ~20% of profits, selling instruments, consumables and services mostly used in drug discovery with ~65% recurring revenues. The manager acknowledges this segment is more cyclical and faces fiercer competition with no regulatory validation lock-in. However, the manager sees a clear longer-term through-cycle trend of growing research budgets and believes life science tools will benefit most directly from AI as LLMs increase the number of hypotheses tested, increasing demand for wet lab instrumentation and consumables. |
Drug Discovery Research Tools AI Genomics | |
QualityThe manager's investment strategy focuses on identifying companies that demonstrate market power, can grow sustainably at abnormally high rates of return, and have built a culture of strong execution, intelligent risk taking and disciplined capital allocation with an obsessive focus on preserving those attributes for decades. Danaher is presented as a precise manifestation of this archetype, with the Danaher Business System (DBS) focusing on highly measurable, granular continuous improvement to deliver incremental value. |
Market Power Capital Allocation Execution Compounding | |
GenomicsThe manager discusses genomics as a major part of the Life Sciences division, where businesses like IDT and Aldevron support the development and manufacturing of cell and gene therapies. However, the manager explicitly states that the $10bn Aldevron acquisition in 2021 has resulted in significant value destruction, with the chances of achieving a satisfactory return now looking thin. Gene therapies have largely remained confined to niche, rare-disease populations, and the mRNA platform has encountered difficulties being applied beyond COVID. |
Gene Therapy Cell Therapy mRNA Aldevron | |
| 2026 Q1 |
AIFund remains voluntarily underexposed to AI theme despite recognizing its potential impact. Manager believes dispersion of outcomes is too wide and questions how profit pools will be distributed across the value chain. Views current AI valuations as excessive at 30-40x earnings or revenues. |
Artificial Intelligence Technology Valuations Infrastructure Semiconductors |
Latin AmericaFund significantly increased exposure to 28% after finding attractive valuations following currency depreciation and investor capitulation. Sees opportunities similar to Brazil's early 1990s transition from hyperinflation to economic liberalization, particularly in Argentina under new government reforms. |
Brazil Argentina Emerging Markets Currency Economic Reform | |
OilInvested in Vista Energy's Vaca Muerta shale assets with break-evens comparable to North American shale but at early development stage. Expects company can double production over five years at 20%+ marginal returns while returning half of market cap to shareholders. |
Shale Argentina Energy Production Returns | |
ValueStrategy focuses on finding situations where returns are underestimated and risks are overestimated, contrasting with AI trade where they see the opposite. Applies bottom-up analysis to identify quality businesses at cheap valuations for reasons irrelevant to long-term investors. |
Valuation Contrarian Bottom-up Quality Disconnect | |
| 2025 Q4 |
AIAI infrastructure plays dominated 2025 returns, with 65% of Russell 2000's return coming from AI infrastructure. The manager views this as a concentrated market levered to a singular theme - essentially a bet on how much CAPEX five companies will spend building data centers. Questions whether the AI trade will persist given its concentration. |
Infrastructure Data Centers CAPEX |
Small CapsSmall caps continued to underperform large caps in 2025. The Russell 2000's returns were dominated by AI infrastructure plays and speculative unprofitable companies, creating extreme bifurcation between unprofitable stocks and quality stocks. Small cap index exposure increasingly means exposure to both AI CAPEX and unprofitable companies. |
Russell 2000 Underperformance Quality | |
QualityQuality businesses today trade at historically cheap multiples despite extreme valuation disparities between winners and losers reaching historic extremes. The manager believes if earnings are the long-term driver of stock prices, the current market dynamics will ultimately reverse in favor of quality. |
Valuation Multiples Earnings | |
| 2025 Q3 |
QualityThe fund focuses on companies with exceptional execution and long-term risk assessment capabilities. They seek businesses with owner-operators who demonstrate Founder's Mindset, combining executional urgency with disciplined capital allocation. These quality companies have delivered mid-teens or higher long-term total shareholder returns through superior business models. |
Execution Owner-operators Returns Moats Compounding |
| 2025 Q2 |
SemiconductorsThe semiconductor industry has grown at ~8% annually for 40 years, driven by exponential innovation. The fund focuses on analog semiconductors, which are more stable than digital chips and have multi-decade product lifecycles. Analog chips condition real-world signals like temperature and pressure, requiring high precision for applications in medical equipment, automotive, and industrial systems. |
Analog Cyclical Manufacturing Automotive Industrial |
OnshoringTI is constructing multiple new fabs in Texas and Utah while ~70% of analog chips are manufactured in East Asia. In today's geopolitical world, having US-based chipmaking capacity is a large asset as companies like Apple, defense industry and carmakers aim to source more locally. TI is uniquely positioned to answer to this new need for supply chain security. |
Manufacturing Geopolitical Supply Chain Defense Domestic | |
Semiconductor CycleThe semiconductor industry is notoriously cyclical with long lead times for capacity expansion while demand changes can be sudden. TI initiated its largest capex cycle while the industry entered one of its largest cyclical downturns, which troughed below the previous cycle bottom. The company is expanding domestic capacity ahead of the upcoming semiconductor upcycle. |
Cyclical Capacity Investment Downturn Recovery | |
| 2025 Q1 |
E-commerceAmazon demonstrates exceptional customer obsession through consistent price reductions, free shipping innovations, and willingness to cannibalize profitable businesses for customer benefit. The company has reduced AWS prices 151 times since 2006 and introduced free shipping thresholds that cut margins but removed customer pain points. This customer-first approach creates sustainable competitive advantages and long-term value creation. |
Customer obsession Free shipping AWS pricing Digital transformation Market leadership |
| 2024 Q4 |
QualityZeno focuses on building a portfolio of incredible companies with Founder Mindset, Market Power and Reinvestment opportunity. They seek businesses that can continually generate high returns on capital over very long periods and through different economic cycles, managed by trustworthy and aligned people. |
Quality Returns Capital Cycles Management |
ResilienceThe fund emphasizes investing in businesses that will protect wealth when the world looks terrible and take advantage of tough times to position themselves even better for good times. They seek companies with resiliency to thrive when economic cycles turn against them. |
Resilience Protection Cycles Downturns Survival | |
| 2024 Q3 |
LuxuryLVMH represents the crown jewel of luxury conglomerates with powerful brand equity and distribution scale. The company has built significant market power through Louis Vuitton and Dior, which have consistently outgrown the industry and increased market share from 19% to 37% among mega-brands since 2016. Despite current cyclical weakness, luxury consumption has compounded at 6% CAGR over 30 years with strong secular tailwinds from globalization of wealth. |
Brand Power Distribution Pricing Power Market Share Desirability |
| 2024 Q2 |
AerospaceGE Aerospace represents the global leading provider of jet engines with approximately 70% market share of commercial engines. The business model consists of low margin engine sales followed by high margin aftermarket services that generate 3.5x the revenue of initial engine sales. The aftermarket dynamic creates one of the largest and most defensible profit pools in the aerospace ecosystem. |
Commercial Aviation Aftermarket Services Market Power Switching Costs Scale Benefits |
| 2024 Q2 |
AerospaceGE Aerospace represents the global leading provider of jet engines with approximately 70% market share of commercial engines. The business model consists of low margin engine sales followed by high margin aftermarket services that generate 3.5x the revenue of initial engine sales. The aftermarket dynamic creates one of the largest and most defensible profit pools in the aerospace ecosystem. |
Commercial Aviation Aftermarket Services Market Power Switching Costs Scale Benefits |
| 2024 Q1 |
QualityThe fund focuses on finding companies that have escaped capitalism's gravitational pull on returns and can earn significant excess profits for extended periods. They seek businesses managed by people with incentives for generational value creation who balance profit maximization with fair treatment of stakeholders. |
Moats Excess Returns Long-term Stakeholders Generational |
| 2023 Q4 |
QualityThe fund applies three rigorous investment criteria: market power, reinvestment opportunity, and founder mindset. Companies must demonstrate all three characteristics to qualify for investment. This quality-focused approach led to significant portfolio changes as existing holdings were tested against these standards. |
Market Power Reinvestment Founder Mindset Quality Criteria Investment Standards |
| 2023 Q4 |
QualityThe fund applies three rigorous investment criteria: market power, reinvestment opportunity, and founder mindset. Companies must demonstrate all three characteristics to qualify for investment. This quality-focused approach led to significant portfolio changes as existing holdings were tested against these standards. |
Market Power Reinvestment Founder Mindset Quality Criteria Investment Standards |
| 2023 Q2 |
Property ManagementAppFolio operates as a vertical market software provider serving the property management industry with an operating system that handles rent collection, maintenance requests, tenant screening, and accounting for property managers. The company serves approximately 20,000 property managers managing 8 million units out of a total addressable market of 79 million units in the US. The business benefits from high switching costs as it serves as a mission-critical operating system used daily by entire property management staffs. |
Property Management Vertical Software SaaS Real Estate Services Workflow Automation |
| 2023 Q2 |
Property ManagementAppFolio operates as a vertical market software provider serving the property management industry with an operating system that handles rent collection, maintenance requests, tenant screening, and accounting for property managers. The company serves approximately 20,000 property managers managing 8 million units out of a total addressable market of 79 million units in the US. The business benefits from high switching costs as it serves as a mission-critical operating system used daily by entire property management staffs. |
Property Management Vertical Software SaaS Real Estate Services Workflow Automation |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | Fund Letters | Zeno | DHR | Danaher Corporation | Diagnostics & Research | Health Care Equipment | Bull | New York Stock Exchange | Aging Population, biologics, Bioprocessing, biotechnology, cash conversion, Chromatography, Danaher Business System, diagnostics, Drug Discovery, Equity, Healthcare Equipment, high margins, life sciences, Market Power, Molecular Diagnostics, Operational Improvement, Razor Razorblade Model, recurring revenue, secular growth, switching costs, Value | Login |
| May 23, 2026 | Fund Letters | Zeno | RENT3.SA | Localiza | Rental & Leasing Services | Specialized Consumer Services | Bull | Brasil Bolsa Balcão | Brazil, Car Rental, economies of scale, Emerging markets, Fleet Management, founder-led, market leader, Value, vertical integration | Login |
| May 23, 2026 | Fund Letters | Zeno | VIST | Vista Energy | Oil & Gas E&P | Oil & Gas Exploration & Production | Bull | New York Stock Exchange | Argentina, Emerging markets, energy, founder-led, Free Cash Flow, oil production, Shale Oil, Vaca Muerta, Value | Login |
| May 23, 2026 | Fund Letters | Zeno | PAX | Patria Investments | Asset Management | Asset Management & Custody Banks | Bull | NASDAQ | alternative investments, asset management, Brazil, Credit, founder-led, infrastructure, Latin America, private equity, Real Estate | Login |
| Jan 21, 2026 | Fund Letters | Cristiano Souza | DHR | Danaher Corporation | Health Care | Life Sciences Tools & Services | Bull | New York Stock Exchange | Capitalallocation, compounding, Governance, Ownership, Spinoffs | Login |
| Jul 17, 2025 | Fund Letters | Zeno | TXN | Texas Instruments Incorporated | Information Technology | Semiconductors & Semiconductor Equipment | Bull | NASDAQ | Analog Semiconductors, automotive, Catalog Products, Cyclical, Free Cash Flow, geopolitical, Industrial, manufacturing, US Domestic Production, vertical integration | Login |
| Jun 30, 2025 | Fund Letters | Cristiano Souza | TXN | Texas Instruments Incorporated | Information Technology | Semiconductors | Bull | NASDAQ | Analog Semiconductors, capital expenditure, Catalog Chips, Free Cash Flow Growth, Supply Chain Security, US Manufacturing, vertical integration | Login |
| Apr 22, 2025 | Fund Letters | Zeno | AMZN | Amazon.com Inc. | Consumer Discretionary | Internet & Direct Marketing Retail | Bull | NASDAQ | AWS, Cloud computing, Competitive Moats, Customer Obsession, e-commerce, Founders Mindset, High returns, innovation, Long-term Value, mega-cap tech | Login |
| Jul 16, 2024 | Fund Letters | Zeno | GE | GE Aerospace | Industrials | Aerospace & Defense | Bull | NYSE | Aerospace, aftermarket services, Commercial Aviation, Defense, Jet Engines, lean manufacturing, market share, Pricing power, secular growth, turnaround | Login |
| - | Fund Letters | Zeno | APPF | AppFolio | Software & Services | Application Software | Bull | NASDAQ | ARPU growth, high switching costs, Long-term Ownership, Market Power, property management, real estate technology, recurring revenue, SaaS, vertical software | Login |
| TICKER | COMMENTARY |
|---|---|
| DHR | In this letter, we will argue that our largest position, Danaher, is a precise manifestation of this archetype of business, clearly demonstrating market power and a rewarding reinvestment opportunity. We will also demonstrate that these are resilient and sustainable attributes that are not properly reflected in the share price, giving us an opportunity to earn an above normal rate of risk-adjusted return. The Biotechnology segment is Danaher's crown jewel, formed through the remarkably successful acquisition of GE's biopharma assets in 2020 and the subsequent integration of Pall's bioprocessing business in 2023. The assets operate under the Cytiva brand, generating ~30% of Danaher's revenues but closer to ~40% of profits. Cytiva sells the equipment and consumables used in bioprocessing, which means the manufacturing of large-molecule drugs (often called biologics) under a classic razor-razorblade model – an instrument is installed almost at cost, with all the money made on high-margin consumables over the contract life. Cytiva has 36% market share, but more importantly it leads the chromatography purification step with an estimated ~70% share. Chromatography is the heart of bioprocessing, where the drug is purified by separating the target molecule from the impurities carried over from the upstream process. As a result, it sets the final purity profile on which the product's safety and efficacy rest, leading to one of the deepest and most expensive lock-ins of the entire process. Little wonder, then, that some chromatography resins carry ~90% gross margins and are a large part of why Danaher earns the best EBIT margins in the industry at ~40%. Danaher's first foray into healthcare was in Diagnostics, which today contributes roughly 40% of revenues and profits. The operating companies in this segment sell instruments and consumables used to perform both clinical and molecular testing. Similar to biotechnology, this is another razor-razorblade, recurring revenue business model, with an estimated 90% of sales coming from higher-margin consumables. Among suppliers Danaher stands out with industry-leading 29% segment EBIT margins, converting over 90% of divisional profits to cash and earning a marginal return in excess of 30% over the past decade. It is worth mentioning that Danaher didn't just buy good assets in diagnostics; rather, it created significant value in successfully implementing DBS. Cepheid is a particularly striking example. At acquisition, the business was barely profitable with a consumables scrap rate of 25%, meaning one-in-four cartridges manufactured were thrown away. Danaher managed to reduce that significantly by implementing lean manufacturing techniques to drive margins to ~30% over a period in which revenue multiplied several-fold. Beckman Diagnostics is another great example, which has been propelled from share donor to share gainer, and we see fertile ground for further operational improvement with the recent ten-billion-dollar Masimo deal which closed last month. The story in Life Sciences which constitutes the remaining ~20% of profits is more convoluted. This is the most diversified segment of the three, selling instruments, consumables and services mostly used in drug discovery with some additional exposure to various industrial and clinical applications. The division earns a low twenties operating margin with ~90% cash conversion. Recurring revenues are still very relevant, but a lower portion of sales compared to the other divisions at ~65%. Having acquired IDT in 2018, Danaher made a much larger bet on the space by acquiring Aldevron in 2021 for almost $10bn. Yet, fast-forward five years, and COVID volumes have plummeted, while the promise of genomics has faced more hurdles than anticipated. Gene therapies have largely remained confined to niche, rare-disease populations, and cell therapies struggle with the complications of moving to 'off-the-shelf' solutions, the key to achieving scale, bringing down costs, and addressing large populations. The mRNA platform, meanwhile, has encountered difficulties being applied beyond COVID. In addition, competitors developed similar capabilities faster than anticipated, widening the range of outcomes. All in all, Aldevron has resulted in significant value destruction, and the chances of achieving a satisfactory return now look thin. Two years later, Danaher acquired Abcam for $5.7bn, a supplier of antibodies and reagents used in research across academia, pharma, and diagnostics. This acquisition, however, has also proved disappointing so far. While DBS worked as expected, expanding margins by five percentage-points in just two years, Abcam's top line growth has been underwhelming as Trump's policies throughout 2025 exacerbated an already weakening research market. Although it's probably still too early to judge this deal as a failure, a rather optimistic scenario is required from here just to deliver a sufficient return. Taking into consideration what it got right and what it got wrong in the construction of Danaher 4.0 we are confident the firm will continue to compound at very attractive returns for a very long time. Disregarding ~40 years of good decisions does not seem rational to us. At a ~5% free-cash-flow yield for a combined business we think can credibly deliver high-single-digit to low-double-digit earnings growth over the next decade, we feel it offers unusually compelling risk-adjusted return characteristics for our investor's capital. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||
